-
Song Yongping and Zhang Wei: Climb the peak, innovate ADC drugs Pola-enabled transplantation and CAR-T therapy, and explore more therapeutic potential
Time of Update: 2022-11-05
What should patients do after CAR-T treatment fails?Star solution expertASCT and CAR-T have unmet needs in R/R DLBCLThe advent of rituximab ushered in the era of immunochemotherapy in the field of lymphoma, and its classic R-CHOP regimen in combination with chemotherapy significantly improved response rates and survival in patients with DLBCL, but about 40% to 50% of patients still failed to achieve remission or relapse after CR.
-
Do you know how many major [CP] are common in the inspection items?
Time of Update: 2022-11-04
Hydroxybutyrate dehydrogenase (HBDH) is a general term for LDH1 and LDH2 containing H subunits, which is meaningful for the diagnosis of myocardial diseases, and because the kidneys also exist, it is necessary to pay attention to the possibility of urinary tumors when HBDH is significantly increased.
-
【JCO】Tumor case study: first-line treatment of mantle cell lymphoma
Time of Update: 2022-11-04
The CALGB/ALLIANCE working group evaluated a methotrexate-fortified RCHOP-like regimen in 78 patients in study 59909, followed by etoposide/araC and auto-HCT, resulting in a median PFS of 5 years for transplant patients.
-
Swollen lymph nodes, inflammation or tumor?
Time of Update: 2022-11-04
How to judge lymphadenopathy?Many people in the physical examination, the report will write that the lymph nodes are enlarged, how to judge that it is bigger?Lymph nodes are about the size of broad beans, under normal circumstances, superficial lymph nodes are relatively small, short diameter is less than 5mm, not easy to touch, and there is no tenderness.
-
Mayo Thousand Studies demonstrated that the interval between the end of NDMM induction therapy and transplantation can affect PFS
Time of Update: 2022-11-04
However, many clinical trials have shown a significant survival benefit with ASCT compared with medical therapy alone, with nearly one-third of patients achieving complete remission (CR) without any additional treatment, and median PFS from diagnosis of 18 months to 2 years.
-
Ulus Travma Acil Cer: Comparison of analgesic consumption in patients with hemophilia and non-hemophilia during knee replacement
Time of Update: 2022-11-04
Figure: Research flowchartThis retrospective study included patients with hemophilia and non-hemophilia TKA who underwent surgery under general anaesthesia from 2001 to 2020.
Figure: Research flowchartThis retrospective study included patients with hemophilia and non-hemophilia TKA who underwent surgery under general anaesthesia from 2001 to 2020.
-
【Cancer Med】Real-world first-line treatment model and outcome of elderly multiple myeloma in China
Time of Update: 2022-11-04
In a recent real-world study in Cancer Medicine, the authors analyzed the first-line treatment models of elderly MM patients from four major medical centers in China (Beijing Jishuitan Hospital, Beijing Chaoyang Hospital, Peking University First Hospital, and Peking Union Medical College Hospital), compared the impact of induction therapy regimen and maintenance therapy on clinical outcomes, and discussed the current real-world practice to provide reference for further improving the survival rate of elderly MM patients in the future.
-
【Leukemia】 852 patients from Tianjin Blood Research Institute compared the MDS WHO 2016 and 2022 classification
Time of Update: 2022-11-04
Clinical features and survival analysis of WHO 2022 MDS types The median survival of patients classified as MDS according to WHO 2016 criteria was 4 years, which decreased to 45 months according to WHO 2022 criteria, with patients with MDS-biTP53 and MDS-f having significantly shorter survival compared with other subtypes (10 months versus 15 months); Figure 4A).
-
Lancet Haematol: Hyper-CVAD sequential berintoolomab for Ph-B-ALL, with a 3-year survival rate of over 80%
Time of Update: 2022-11-04
Blinatumomab is a CD19/CD3 bispecific T cell adaptor with excellent efficacy in monotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), and its early experience as the first-line treatment for older (age> 65 years) Philadelphia chromosome (Ph)-positive and Ph-negative ALL (a population with poor outcomes due to poor biology and poor tolerance to chemotherapy) is also encouraging.
-
Science Translational Medicine: CRISPR gene-edited universal CAR-T, clinical trial results for the treatment of childhood leukemia released
Time of Update: 2022-11-04
The research team used next-generation CRISPR-Cas9 gene editing technology to knock out TRAC and CD52 of CAR19 T cells, construct a universal CAR-T cell, TT52CAR19 T cells, and conducted a phase 1 clinical trial for the treatment of childhood B-cell acute lymphoblastic leukemia (B-ALL).
-
Cancer Med: First-line treatment outcomes and clinical outcomes in older multiple myeloma patients in real-world settings: a multicenter retrospective study in China.
Time of Update: 2022-11-04
immunomodulators, immunomodulators; MM, multiple myeloma; operating system, overall survival; PFS, progression-free survival; PI, proteasome inhibitorsFigure 2: Survival curves of elderly patients in different maintenance treatment groups.
immunomodulators, immunomodulators; MM, multiple myeloma; operating system, overall survival; PFS, progression-free survival; PI, proteasome inhibitorsFigure 2: Survival curves of elderly patients in different maintenance treatment groups.
-
One case of acute B-lymphoblastic leukemia with BCR-ABL1
Time of Update: 2022-11-04
preface Acute lymphoblastic leukemia (ALL) is a type of acute leukemia that mainly originates from B or T line lymphoid progenitor cells, which abnormally proliferate and aggregate in the bone marrow,
-
STM: CRISPR gene-edited universal CAR-T, clinical trial results for the treatment of childhood leukemia released
Time of Update: 2022-11-04
The research team used next-generation CRISPR-Cas9 gene editing technology to knock out TRAC and CD52 of CAR19 T cells, construct a universal CAR-T cell, TT52CAR19 T cells, and conducted a phase 1 clinical trial for the treatment of childhood B-cell acute lymphoblastic leukemia (B-ALL).
-
Ann Hematol: Safety and efficacy of daramalimumab in patients with relapsed or refractory multiple myeloma in China: a Phase 1 dose-escalation study
Time of Update: 2022-11-04
In the daramalimumab 16 mg / kg group (n = 47), the median number of patients received prior therapy was 4 lines; 32% were refractory to PI and IMiD, and 79% refractory to their last previous treatment.
-
D-dimer (D-dimer) clinical application 2.0
Time of Update: 2022-11-04
The reason why D-dimer dynamic monitoring can be used to predict thrombosis and evaluate anticoagulant effect is inseparable from the following characteristics in its clinical application.
-
JHO: Dara-DCEP treatment with extramedullary lesions RRMM, ORR 67.7%, PFS 5 months
Time of Update: 2022-11-04
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
-
Anticancer Res: Effect of interleukin-18 genotype on the risk of acute lymphoblastic leukemia in children in Taiwan
Time of Update: 2022-11-04
Therefore, the current study by a research team aims to investigate the contribution of IL-18 polymorphisms to the risk of acute lymphoblastic leukemia (ALL) in children in Taiwan.
-
【JACC CardioOncol】Danish epidemiological study: MGUS patients have a widespread increase in cardiovascular risk
Time of Update: 2022-11-04
morbidity In age- and sex-adjusted logistic regression analysis, patients with MGUS had significantly higher odds for most cardiovascular diseases, including heart failure, atrial fibrillation, acute myocardial infarction, ischaemic stroke, aortic aneurysm, aortic dissection, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, conduction disease, pericarditis, peripheral artery disease, aortic aneurysm, venous thromboembolism, and cardiac device implantation compared with control patients (Table 2).
-
【JHO】Chinese expert consensus on clinical practice of primary CNS lymphoma based on evidence
Time of Update: 2022-11-04
At baseline and follow-up, evaluation of neurocognitive function in patients with PCNSL is recommended Suggested flow chart of diagnosis and treatment ReferencesTong Chen, Yuanbo Liu, Yang Wang,et al.
-
【Am J Hematol】Diagnosis and Treatment of Follicular Lymphoma (2023 Update)
Time of Update: 2022-11-04
In a PRIMA phase III study of 1018 FL patients who had not previously received chemotherapy, patients in response to immunochemotherapy (CVP-R, CHOP-R, or FCM-R) were randomly assigned to receive rituximab (375 mg/m2 every 8 weeks for 24 months) or placebo maintenance therapy 。 At a median follow-up of 36 months after randomization, PFS rates were higher in the rituximab maintenance group (75% vs.
